Brief: Minerva Neurosciences Announces The NDA Filing For Roluperidone For The Treatment Of Negative Symptoms In Schizophrenia
01/05/2023 13:40
May 1 (Reuters) - Minerva Neurosciences Inc NERV.O :
* MINERVA NEUROSCIENCES ANNOUNCES THE NDA FILING FOR
ROLUPERIDONE
FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
* MINERVA NEUROSCIENCES - DECISION TO FILE NDA FOLLOWS CO'S
REQUEST FOR FORMAL DISPUTE RESOLUTION AND APPEAL OF FDA'S
OCTOBER 2022 REFUSE TO FILE LETTER
Source text for Eikon: ID:nGNE9zPlh
Further company coverage: NERV.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Minerva Neurosciences
See all newsU.S. RESEARCH ROUNDUP-Cisco, Fox Corp, Target
Brief: Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates
Brief: Minerva Neurosciences - To Offer And Sell Up To $75 Million In Common Stock Through Leerink Partners
Brief: Minerva Announces Leadership Transition
Minerva Neurosciences Q4 net loss widens on non-cash financing charges